SG11201907472QA - Composition for inhibiting myofibrosis - Google Patents

Composition for inhibiting myofibrosis

Info

Publication number
SG11201907472QA
SG11201907472QA SG11201907472QA SG11201907472QA SG11201907472QA SG 11201907472Q A SG11201907472Q A SG 11201907472QA SG 11201907472Q A SG11201907472Q A SG 11201907472QA SG 11201907472Q A SG11201907472Q A SG 11201907472QA SG 11201907472Q A SG11201907472Q A SG 11201907472QA
Authority
SG
Singapore
Prior art keywords
myofibrosis
inhibiting
composition
present
safely
Prior art date
Application number
SG11201907472QA
Inventor
Daisuke Yoshida
Yuta Otsuka
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of SG11201907472QA publication Critical patent/SG11201907472QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention aims to provide a composition for inhibiting myofibrosis, which contains, as an active 5 ingredient, a component that is safely ingestible for a long period of time; and a method of safely inhibiting myofibrosis. The present invention provides a composition for inhibiting myofibrosis containing quercetin or a glycoside thereof as an active ingredient.
SG11201907472QA 2017-03-10 2018-03-08 Composition for inhibiting myofibrosis SG11201907472QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017046265 2017-03-10
PCT/JP2018/008960 WO2018164221A1 (en) 2017-03-10 2018-03-08 Composition for inhibiting myofibrosis

Publications (1)

Publication Number Publication Date
SG11201907472QA true SG11201907472QA (en) 2019-09-27

Family

ID=63448674

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907472QA SG11201907472QA (en) 2017-03-10 2018-03-08 Composition for inhibiting myofibrosis

Country Status (6)

Country Link
US (1) US20190388387A1 (en)
JP (2) JP7379152B2 (en)
CN (1) CN110312510A (en)
CA (1) CA3055164A1 (en)
SG (1) SG11201907472QA (en)
WO (1) WO2018164221A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021106760A1 (en) * 2019-11-27 2021-06-03
WO2023017654A1 (en) * 2021-08-11 2023-02-16 株式会社島津製作所 Prediction device, prediction method, and prediction program

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201809153WA (en) * 2014-04-28 2018-11-29 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside
SG11201708158PA (en) * 2015-04-27 2017-11-29 Suntory Holdings Ltd Composition for suppressing muscular fatty change

Also Published As

Publication number Publication date
WO2018164221A1 (en) 2018-09-13
CN110312510A (en) 2019-10-08
JPWO2018164221A1 (en) 2020-01-09
CA3055164A1 (en) 2018-09-13
US20190388387A1 (en) 2019-12-26
JP2022079551A (en) 2022-05-26
JP7379152B2 (en) 2023-11-14
TW201836669A (en) 2018-10-16

Similar Documents

Publication Publication Date Title
MY194893A (en) Muscle atrophy inhibitor containing quercetin glycoside
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2018006286A (en) Pyrazole acc inhibitors and uses thereof.
MX2018009773A (en) Heteroaryl inhibitors of pad4.
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MX2018001990A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
MX2020001793A (en) Ahr inhibitors and uses thereof.
NZ718373A (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MY192425A (en) Polymorphs
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
GEP20217318B (en) Pyrazole magl inhibitors
MX2015015162A (en) Uric acid level lowering agent.
PH12019502110A1 (en) Pharmaceutical combination comprising ponesimod
MX2021001471A (en) Substituted benzimidazoles as pad4 inhibitors.
SG11201804160SA (en) Composition for inhibiting carnosine dipeptidase
PH12020550947A1 (en) Polymorphs
SG11201907472QA (en) Composition for inhibiting myofibrosis
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes
MX2019015524A (en) Immunogenic compositions.
PH12017501897A1 (en) 2-thiopyrimidinones